公开(公告)号：US10377988B2

公开(公告)日：2019-08-13

申请号：US15533103

申请日：2016-01-22

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Mark Rubinstein ,  David Cole

IPC: C12N5/0783 ,  A61K35/17 ,  A61K38/17 ,  A61K38/20 ,  C07K14/715 ,  C12N15/85 ,  C07K14/705

Abstract: Cells, such a T-cells, are provided that comprise cytokine receptors having increased activity in response to their ligand. For example, cell can comprise IL-2 and/or IL-15 receptors having increased surface expression or signaling activity. Cells of the embodiments have a significant growth advantage in the presence of cytokines and can be used, e.g., for enhanced adoptive cell transfer therapies.

公开(公告)号：US11230698B2

公开(公告)日：2022-01-25

申请号：US16448208

申请日：2019-06-21

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Mark Rubinstein ,  David Cole

IPC: C12N5/0783 ,  A61K35/17 ,  A61K38/17 ,  A61K38/20 ,  C07K14/705 ,  C07K14/715 ,  C12N15/85

Abstract: Cells, such a T-cells, are provided that comprise cytokine receptors having increased activity in response to their ligand. For example, cell can comprise IL-2 and/or IL-15 receptors having increased surface expression or signaling activity. Cells of the embodiments have a significant growth advantage in the presence of cytokines and can be used, e.g., for enhanced adoptive cell transfer therapies.